Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort

BACKGROUND: Optimization of treatment with biologics is currently an unmet need for patients with ulcerative colitis (UC). Real-world studies provide neutral estimates of drug efficacy and safety within unselected patient populations and allow for the recognition of specific characteristics that aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Bamias, Giorgos, Kokkotis, Georgios, Gizis, Michalis, Kapizioni, Christina, Karmiris, Konstantinos, Koureta, Evgenia, Kyriakos, Nikolaos, Leonidakis, Georgios, Makris, Konstantinos, Markopoulos, Panagiotis, Michalopoulos, Georgios, Michopoulos, Spyridon, Papaconstantinou, Ioannis, Polymeros, Dimitrios, Siakavellas, Spyros I., Triantafyllou, Konstantinos, Tsironi, Eftychia, Tsoukali, Emmanouela, Tzouvala, Maria, Viazis, Nikos, Xourafas, Vassileios, Zacharopoulou, Eirini, Zampeli, Evanthia, Zografos, Konstantinos, Papatheodoridis, George, Mantzaris, Gerasimos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942521/
https://www.ncbi.nlm.nih.gov/pubmed/33751325
http://dx.doi.org/10.1007/s10620-021-06907-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7942521/
https://www.ncbi.nlm.nih.gov/pubmed/33751325
http://dx.doi.org/10.1007/s10620-021-06907-5

Ejemplares similares